Search results for "block"

showing 10 items of 1177 documents

Regulating blockchain for sustainability? The critical relationship between digital innovation, regulation, and electricity governance

2021

Abstract Blockchain technology has found several innovative applications in the electricity industry. However, its potential has still to be discovered. This is partly due to the role that regulation plays in electricity markets. To be introduced, experimented with, and eventually adopted on a commercial scale, blockchain-supported innovations need to fit the existing regulatory framework or the rules to be reshaped or updated. We focus on energy regulators' possible responses to the blockchain-enhanced market operations (both from the incumbents and potential newcomers), suggesting a monitoring mechanism that can support innovation.

020203 distributed computingCommercial scaleBlockchainRenewable Energy Sustainability and the Environmentbusiness.industry020209 energyCorporate governanceEnergy Engineering and Power Technology02 engineering and technologySettore ING-IND/33 - Sistemi Elettrici Per L'EnergiaFuel TechnologyNuclear Energy and EngineeringSustainability0202 electrical engineering electronic engineering information engineeringBlockchain Energy market Innovation RegulationBusinessElectricityElectric power industrySettore SECS-P/08 - Economia E Gestione Delle ImpreseSocial Sciences (miscellaneous)Industrial organizationEnergy Research & Social Science
researchProduct

Detection of algorithmically generated malicious domain names using masked N-grams

2019

Abstract Malware detection is a challenge that has increased in complexity in the last few years. A widely adopted strategy is to detect malware by means of analyzing network traffic, capturing the communications with their command and control (C&C) servers. However, some malware families have shifted to a stealthier communication strategy, since anti-malware companies maintain blacklists of known malicious locations. Instead of using static IP addresses or domain names, they algorithmically generate domain names that may host their C&C servers. Hence, blacklist approaches become ineffective since the number of domain names to block is large and varies from time to time. In this paper, we i…

0209 industrial biotechnologyDomain generation algorithmComputer scienceGeneral Engineering02 engineering and technologycomputer.software_genreBlacklistComputer Science ApplicationsRandom forestDomain (software engineering)020901 industrial engineering & automationArtificial IntelligenceServer0202 electrical engineering electronic engineering information engineeringMalware020201 artificial intelligence & image processingData miningcomputerHost (network)Block (data storage)Expert Systems with Applications
researchProduct

Single block 3D numerical model for linear friction welding of titanium alloy

2018

A two-stage approach for the simulation of Linear Friction Welding is presented. The proposed model, developed using the commercial simulation package DEFORM, is 3D Lagrangian, thermo-mechanically coupled. The first phase of the process was modelled with two distinct workpieces, while the remaining phases were simulated using a single-block model. The Piwnik–Plata criterion was set up and used to determine the shifting from the dual object to the single-block model. The model, validated against experimental temperature measurements, is able to predict the main field variables distributions with varying process parameters. Titanium alpha and beta phases evolution during the whole process has…

0209 industrial biotechnologyMaterials scienceFinite element method titanium linear friction welding Ti6Al4VTitanium alloychemistry.chemical_element02 engineering and technology021001 nanoscience & nanotechnologyCondensed Matter PhysicsFinite element methodsymbols.namesake020901 industrial engineering & automationchemistryBlock (telecommunications)symbolsGeneral Materials ScienceFriction weldingComposite material0210 nano-technologySettore ING-IND/16 - Tecnologie E Sistemi Di LavorazioneLagrangianTitanium
researchProduct

Leveraging Partnerships with Logistics Service Providers in Humanitarian Supply Chains by Blockchain-based Smart Contracts

2019

As humanitarian organizations are struggling to reach an increasing number of beneficiaries, humanitarian-business partnerships, such as the use of logistics service providers (LSPs), promise to improve effectivity and efficiency of humanitarian assistance. Blockchain-based smart contracts which ensure automation, transparency, and efficiency promise to facilitate partnerships, particularly if trust is low. In this paper, blockchain-based smart contracts are critically examined for their application to humanitarian supply chains (HSCs). We identify various adoption barriers which we categorize into organizational, technological, and environmental. As the use of blockchain-based smart contra…

0209 industrial biotechnologyPartnershipsProcess managementBlockchainSupply chain020208 electrical & electronic engineeringComputerApplications_COMPUTERSINOTHERSYSTEMS02 engineering and technologyService providerTransparency (behavior)Humanitarian supply chain020901 industrial engineering & automationBlockchainControl and Systems Engineering0202 electrical engineering electronic engineering information engineeringLogistics service providersBusinessSmart contractsProceedings of IFAC MIM 2019
researchProduct

Exploring the application of blockchain to humanitarian supply chains: insights from Humanitarian Supply Blockchain pilot project

2021

PurposeSome studies and reports have recently suggested using blockchain technology to improve transparency and trust in humanitarian supply chains (HSCs). However, evidence-based studies to display the utility and applicability of blockchains in HSCs are missing in the literature. This paper aims to investigate the key drivers and barriers of blockchain application to HSCs and explore whether evidence could support that the application of blockchain improves transparency and trust in HSCs.Design/methodology/approachThis paper puts forward a two-stage approach to explore the blockchain application in HSCs: an initial exploration of humanitarian practitioners and academicians interested in b…

021103 operations researchBlockchainKnowledge managementbusiness.industryStrategy and ManagementSupply chainCorporate governance05 social sciences0211 other engineering and technologiesGeneral Decision Sciences02 engineering and technologyTransparency (behavior)VDP::Samfunnsvitenskap: 200::Økonomi: 210Management of Technology and InnovationGeneral partnership0502 economics and businessAccountabilityAdded valueBusinessInternational development050203 business & managementInternational Journal of Operations & Production Management
researchProduct

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directo…

2020

Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present…

0301 basic medicineAngiotensin-Converting Enzyme InhibitorsDiseaseoutcomescardiovascular diseases; COVID-19; hypertension; infection; outcomes; Betacoronavirus; COVID-19; Cardiovascular Diseases; Humans; Hypertension; Italy; SARS-CoV-2; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronavirus Infections; Pandemics; Pneumonia Viral; Renin-Angiotensin SystemRenin-Angiotensin System0302 clinical medicinecardiovascular diseaseViralAngiotensin Receptor AntagonistsbiologyAngiotensin Receptor AntagonistAntihypertensive AgentItalyoutcomeAngiotensin Receptor BlockersCoronavirus InfectionsCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)Pneumonia ViralBetacoronavirusAngiotensin Receptor Antagonists03 medical and health sciencesPharmacotherapyRenin–angiotensin systemInternal MedicinemedicineHumansIntensive care medicinePandemicsAntihypertensive Agentsoutcomes.BetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryOutbreakCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin-converting enzymePneumoniacardiovascular diseases; COVID-19; hypertension; infection; outcomesinfectioncardiovascular diseases030104 developmental biologybiology.proteincardiovascular diseases; COVID-19; hypertension; infection; outcomes; betacoronavirus; cardiovascular diseases; humans; hypertension; Italy; angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; antihypertensive agents; coronavirus infections; pandemics; pneumonia viral; renin-angiotensin systembusiness030217 neurology & neurosurgery
researchProduct

CD36-fibrin interaction propagates FXI-dependent thrombin generation of human platelets.

2019

Thrombin converts fibrinogen to fibrin and activates blood and vascular cells in thrombo-inflammatory diseases. Platelets are amplifiers of thrombin formation when activated by leukocyte- and vascular cell-derived thrombin. CD36 on platelets acts as sensitizer for molecules with damage-associated molecular patterns, thereby increasing platelet reactivity. Here, we investigated the role of CD36 in thrombin-generation on human platelets, including selected patients with advanced chronic kidney disease (CKD). Platelets deficient in CD36 or blocked by anti-CD36 antibody FA6.152 showed impaired thrombin generation triggered by thrombin in calibrated automated thrombography. Using platelets with …

0301 basic medicineBlood PlateletsCD36 AntigensCD36InflammationFibrinogenBiochemistryFibrin03 medical and health sciences0302 clinical medicineThrombinBlocking antibodyGeneticsmedicineHumansPlateletRenal Insufficiency ChronicMolecular BiologyFactor XIFibrinbiologyChemistryCell adhesion moleculeThrombinPlatelet ActivationBlood Coagulation FactorsCell biology030104 developmental biologybiology.proteinmedicine.symptom030217 neurology & neurosurgerycirculatory and respiratory physiologyBiotechnologymedicine.drugFASEB journal : official publication of the Federation of American Societies for Experimental BiologyREFERENCES
researchProduct

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

2016

AbstractWe have reviewed the effects of angiotensin II type 1 receptor antagonists (ARBs) in various animal models of hypertension, atherosclerosis, cardiac function, hypertrophy and fibrosis, glucose and lipid metabolism, and renal function and morphology. Those of azilsartan and telmisartan have been included comprehensively whereas those of other ARBs have been included systematically but without intention of completeness. ARBs as a class lower blood pressure in established hypertension and prevent hypertension development in all applicable animal models except those with a markedly suppressed renin–angiotensin system; blood pressure lowering even persists for a considerable time after d…

0301 basic medicineBlood Pressure030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesBenzoatesAnimals Genetically ModifiedRenin-Angiotensin SystemGene Knockout Techniques0302 clinical medicineAzilsartanPharmacology (medical)TelmisartanOxadiazolesKidneybiologyStrokemedicine.anatomical_structureCardiovascular DiseasesHypertensionDrug Therapy Combinationmedicine.drugmedicine.medical_specialty03 medical and health sciencesMetabolic DiseasesCulture TechniquesInternal medicineRenin–angiotensin systemmedicineAnimalsHumansAntihypertensive AgentsPharmacologyAngiotensin II receptor type 1business.industryAngiotensin-converting enzymeAtherosclerosisLipid Metabolismmedicine.diseaseDisease Models AnimalGlucose030104 developmental biologyBlood pressureEndocrinologyPathophysiology of hypertensionbiology.proteinBenzimidazolesEndothelium VascularTelmisartanbusinessAngiotensin II Type 1 Receptor BlockersPharmacology & Therapeutics
researchProduct

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

2021

Simple Summary The immune checkpoint blockade (ICB), and concretely the blockade of the PD1/PDL1 axis, has opened up a new standard of treatment for non-small cell lung cancer (NSCLC). However, despite substantial advances in clinical care, many patients still remain refractory to these therapies. Biomarkers such as PD-L1 expression and tumor mutational burden have been associated with ICB efficacy, but the mechanisms underlying variable responses are not yet fully understood. Recently, the differential composition of the gut microbiota was studied as one of the variables accounting for interpatient heterogeneity in ICB responses. To better understand the potential role of the gut microbiot…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentAntibioticsGut floradigestive systemArticle03 medical and health sciences0302 clinical medicinemedicineLung cancerRC254-282non-small cell lung cancerbiologygut microbiotabusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyimmune checkpoint blockademedicine.diseasebiology.organism_classificationImmune checkpointBlockade030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyBiomarker (medicine)biomarkernext-generation sequencingimmunotherapybusinessProgressive disease
researchProduct

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

2019

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the…

0301 basic medicineCancer Researchmedicine.medical_specialtyAvelumabSkin NeoplasmsPrognosimedicine.medical_treatmentPembrolizumabImmune checkpoint inhibitorCochrane LibraryB7-H1 AntigenSettore MED/13 - EndocrinologiaAvelumab03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicineMerkel cell carcinomaNeuroendocrine tumoursNeuroendocrine tumourmedicineAnimalsHumansSkin NeoplasmIntensive care medicineMerkel cell carcinomabusiness.industryAnimalAntibodies MonoclonalGeneral MedicineImmunotherapymedicine.diseasePrognosisImmune checkpointBlockadeClinical trialCarcinoma Merkel Cell030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyTherapyAvelumab; Immune checkpoint inhibitors; Merkel cell carcinoma; Neuroendocrine tumours; Pembrolizumab; TherapybusinessPembrolizumabmedicine.drugHuman
researchProduct